Mar 01, 2013, 05.03 PM | Source: Moneycontrol.com
Angel Broking has maintained a neutral rating on Ranbaxy Laboratories (Ranbaxy) in its February 27, 2013 research report.
, Angel Broking |
"Ranbaxy Laboratories (Ranbaxy) reported a lower than expected performance in its 4QCY2012 results. While the company’s top-line de-grew 28.8% during the quarter, the OPM came much below expectation at 3.2% (vs an expected 9.3%). The adjusted net loss came in at Rs 25cr. The operating performance of the company continues to be impacted and there is no clarity on the consent decree. While the valuations have become attractive on EV/sales basis, we would wait for a few more quarters before we review the stock.
Lower-than-expected performance: Ranbaxy reported net sales of Rs 2,671cr, down 28.8% yoy, and above our estimate of Rs 2,525cr. The gross margin declined by 15.3% to 56.8%, which along with a lower rise in staff expenditure, led the OPM to come at 3.2%, much lower than 21.7% in 4QCY2011. This was lower than our expectation of 9.3%. This led to the company posting an adjusted net loss of Rs 25cr.
Outlook and valuation: The stock is trading at attractive valuations of EV/sales of 1.2x CY2014E. While the valuation is very attractive in comparison to its peers, given the low profitability in the core business and uncertainty on the USFDA front, we maintain our Neutral rating on the stock," says Angel Broking research report.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
To read the full report click here
Divis Laboratories: Outcome of board meeting
Divis Laboratories Ltd has informed BSE that the B
Lupin Q3: Prakash Diwan upbeat; Angle Broking neutral
Gold prices expected to trade higher: Angel Commodities
According to Angel Commodities, gold prices are ex
Rekvina Laboratories' board meeting on February 11, 2016
Rekvina Laboratories Ltd has informed BSE that the
BSE brokers forum seeks industry status for stock broking
"The stock broking fraternity, once given industry
Choksi Laboratories' board meeting on February 13, 2016
Choksi Laboratories Ltd has informed BSE that a me